Lumexa Imaging Holdings, Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Lumexa Imaging Holdings, Inc. (LMRI) operates as a network of diagnostic outpatient imaging centers across 13 states. As of the reporting date, the company operated 189 centers, consolidating 103 and accounting for 86 via the equity method through joint ventures with health systems. The company recently completed an IPO in December 2025 and refinanced its senior secured credit facility in the same month.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $252.5 million | $245.0 million |
| Net Income (Loss) | $1.7 million | ($7.7 million) |
| Adjusted EBITDA | $51.2 million | $51.0 million |
| Operating Cash Flow | $2.9 million | ($14.0 million) |
| Cash and Equivalents | $51.2 million | $7.3 million |
| Total Debt (Gross) | $842.0 million | $844.0 million |
| Interest Expense | $16.3 million | $29.8 million |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $1.7 million in Q1 2026, a significant improvement from a net loss of $7.7 million in Q1 2025. This was primarily driven by a $13.5 million reduction in interest expense following the December 2025 debt refinancing.
- Revenue Growth: Total revenues increased by 3.1% year-over-year. Net patient service revenue grew 2.6%, driven by a 2.8% increase in consolidated same-center revenue (0.5% volume growth and 2.3% price growth).
- Cash Flow Improvement: Operating cash flow swung from a $14.0 million outflow in Q1 2025 to a $2.9 million inflow in Q1 2026, largely due to reduced interest payments and improved working capital management.
- Segment Performance: The Professional Services segment saw Adjusted EBITDA increase by 39.8% to $12.8 million, while the Outpatient Imaging Centers segment saw Adjusted EBITDA decrease by 8.2% to $38.4 million due to higher salary and supply costs.
Outlook, Risks, and Contingencies
- Debt Refinancing: In December 2025, the company refinanced its term loan to $825 million at SOFR + 3.0% (down from SOFR + 4.75%), extending maturity to 2032. This significantly reduced interest costs.
- Cybersecurity Incident: On April 15, 2026, the company discovered a vendor data breach involving protected health information. Management states there has been no material interruption to operations and does not currently expect a material adverse financial effect, though remediation costs are being evaluated.
- Internal Control Weaknesses: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in the control environment, risk assessment, revenue accounting, segregation of duties, and IT general controls. Remediation plans are underway but not yet complete.
- Seasonality: Management notes that Q1 typically sees the lowest procedure volumes due to high-deductible health plan resets and winter weather impacts.
Investor Verification Checklist
- Verify the status of remediation efforts for the disclosed material weaknesses in internal controls over financial reporting.
- Monitor the financial impact and potential liabilities arising from the April 2026 vendor data breach.
- Assess the sustainability of the 2.3% net revenue per scan growth amidst competitive reimbursement pressures.
- Review the cash distribution trends from unconsolidated affiliates ($17.7 million in Q1 2026) versus equity earnings ($15.0 million) to gauge liquidity support from joint ventures.
- Confirm compliance with the new debt covenants under the Amended Credit Agreement, specifically regarding leverage ratios if revolving credit usage increases.